These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25880143)

  • 1. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
    Zhang C; Wu Y; Dong Y; Xu H; Zhao L
    Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-decorated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting delivery: optimization and in vivo antitumor activity.
    Zhang C; Zhang Z; Zhao L
    Drug Deliv; 2016 Jun; 23(5):1830-7. PubMed ID: 26652055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
    Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
    Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy.
    Wu G; Wang Z; Bian X; Du X; Wei C
    Pharm Biol; 2014 Aug; 52(8):978-82. PubMed ID: 25017652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A folate modified pH sensitive targeted polymeric micelle alleviated systemic toxicity of doxorubicin (DOX) in multi-drug resistant tumor bearing mice.
    Li X; Yang X; Lin Z; Wang D; Mei D; He B; Wang X; Wang X; Zhang Q; Gao W
    Eur J Pharm Sci; 2015 Aug; 76():95-101. PubMed ID: 25917524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation.
    Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F
    Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-functional core-shell Fe
    S R; M P
    Colloids Surf B Biointerfaces; 2019 Feb; 174():252-259. PubMed ID: 30469046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres.
    Shen Z; Li Y; Kohama K; Oneill B; Bi J
    Pharmacol Res; 2011 Jan; 63(1):51-8. PubMed ID: 21035550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
    Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
    Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multi-Functional Tumor Theranostic Nanoplatform for MRI Guided Photothermal-Chemotherapy.
    Shi J; Wang B; Chen Z; Liu W; Pan J; Hou L; Zhang Z
    Pharm Res; 2016 Jun; 33(6):1472-85. PubMed ID: 26984128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
    Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
    Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate.
    Yang T; Xu L; Li B; Li W; Ma X; Fan L; Lee RJ; Xu C; Xiang G
    Int J Nanomedicine; 2017; 12():2505-2515. PubMed ID: 28408821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved antitumor activity and reduced toxicity of doxorubicin encapsulated in poly(ε-caprolactone) nanoparticles in lung and breast cancer treatment: An in vitro and in vivo study.
    Cabeza L; Ortiz R; Prados J; Delgado ÁV; Martín-Villena MJ; Clares B; Perazzoli G; Entrena JM; Melguizo C; Arias JL
    Eur J Pharm Sci; 2017 May; 102():24-34. PubMed ID: 28219748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
    Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
    J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
    Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
    Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
    Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin.
    Assumpção JU; Campos ML; Ferraz Nogueira Filho MA; Pestana KC; Baldan HM; Formariz Pilon TP; de Oliveira AG; Peccinini RG
    J Pharm Sci; 2013 Jan; 102(1):289-96. PubMed ID: 23150468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.